Zastosowanie toksyny botulinowej typu A (BTx A) u dzieci z nadaktywnym i/lub spastycznym wypieraczem -- doniesienie wstępne

Sulisławski, Janusz; Urbanowicz, Wiesław
September 2008
Polish Journal of Urology / Urologia Polska;2008, Vol. 61 Issue 4, p307
Academic Journal
Introduction. Neurogenic disorders of the urinary bladder in children are in most cases due to myelomeningocele. Standard therapy is not effective in about 10% patients. These cases require surgical procedures such as urinary bladder augmentation. These procedures are associated with surgical and metabolic complications. The aim of the study. This is a preliminary report of the use of botulinum toxin in children "resistant" to standard therapy with type III neurogenic urinary bladder. Material and methods. Among 212 children with neurogenic bladder, classical therapy was not effective in 20 cases. All these cases were children with type III neurogenic bladder. In these cases botulinum toxin A was injected into detrusor at 10-12 U/ kg b.w. dose, but the total dose did not exceed 300 U. Therapeutic effects was assessed by cystometric investigations performed monthly throughout a 9 month period. Moreover, control VCUG was executed after 3 months. T-test for relative variables was used for statistical evaluation of the obtained parameters. Conclusions. Type A botulinum toxin is safe and do not provokes any side effects. Statistically, it results in the improvement of cystometric investigation parameters. Temporary action of the BTx A present the limitation of this treatment method. Its use allows to postpone the decision concerning extensive surgical procedure - urinary bladder augmentation in children.


Related Articles

  • Long-term follow-up after botulinum toxin A (BT X-A) injection into the detrusor for treatment of neurogenic detrusor hyperactivity in children. Zeino, Mazen; Becker, Tanja; Koen, Mark; Berger, Christoph; Riccabona, Marcus // Central European Journal of Urology;2012, Vol. 65 Issue 3, p156 

    Purpose. To prove the long-term efficacy of BTX-A injection in the management of children with neurogenic detrusor hyperactivity. Materials and methods. 28 out of 145 children with neurogenic bladder (15 male and 13 female, mean age 10.7 years) who were treated between 2002 and 2010 and became...

  • Repeated injections of intradetrusor onabotulinumtoxinA as adjunctive treatment of children with neurogenic bladder. Sager, Cristian; Burek, Carol; Bortagaray, Juan; Corbetta, Juan; Weller, Santiago; Durán, Victor; Lopez, Juan // Pediatric Surgery International;Jan2014, Vol. 30 Issue 1, p79 

    Aim: To evaluate the effects of repeated injections of onabotulinumtoxinA in children with neurogenic bladders refractory to conventional treatment. Patients and methods: A total of 26 children with neurogenic bladder were prospectively studied. Some patients received up to four repeat...

  • Outcome on renal function in children with neurogenic bladder dysfunction of a standardised follow-up programme. Wide, Peter; Gladh, Gunilla; Mattsson, Sven // Cerebrospinal Fluid Research;2007 Supplement 1, Vol. 4, Special section p1 

    Background Renal damage still constitutes a major reason for morbidity and mortality in persons with Spina Bifida [1]. Clean intermittent catheterisation is the cornerstone in treatment of neurogenic bladder dysfunction often combined with anticholinergics [2]. Multiple techniques of renal...

  • Success Rate and Patients' Satisfaction Following Intradetrusor Dysport Injection in Patients with Detrusor Overactivity: A Comparative Study of Idiopathic and Neurogenic Types of Detrusor Overactivity. Shakeri, Saeed; Mohammadian, Reza; Aminsharifi, Alireza; Ariafar, Ali; Vaghedashti, Jalal; Yazdani, Maryam; Yadollahi, Mahnza; Emadmarvasti, Vahid; Baharikhoob, Amir // Urology Journal;Winter2014, Vol. 11 Issue 1, p1289 

    Purpose: To evaluate the efficacy of intradetrusor Dysport (a type of botulinum toxin type A) injection in patients with idiopathic or neurogenic detrusor overactivity, who were refractory to antimuscarinic drugs, and to compare the efficacy of Dysport injection in both groups. Materials and...

  • Allergan reports positive opinion for new Botox use in Europe.  // Medical Device Daily;8/9/2011, Vol. 15 Issue 148, p1 

    The article reports that Botox (botulinum toxin A) has received positive opinion from the Irish Medicines Board (IMB). According to Allergan, IMB gave positive remarks on the use of Botox for urinary incontinence management in adult patients with neurogenic detrusor overactivity (NDO) secondary...

  • The surgical management of the refractory overactive bladder. Vasdev, Nikhil; Biles, Benjamin D.; Sandher, Raveen; Hasan, Tahseen S. // Indian Journal of Urology;Apr-Jun2010, Vol. 26 Issue 2, p263 

    The refractory overactive bladder is a clinically challenging entity to manage and affects millions of people worldwide. Current surgical treatment options include botulinum toxin type A, sacral neuromodulation, and bladder reconstruction surgery all of which require careful attention to the...

  • Laparoscopic Ureterocystoplasty with Mitrofanoff System. Landa Juárez, Sergio; Fernández, Ana María Castillo; Castro, Niccolo Ruiz; De La Cruz Yañez, Hermilo; Hernández, Carlos García // Journal of Laparoendoscopic & Advanced Surgical Techniques;Jun2014, Vol. 24 Issue 6, p422 

    Purpose: To describe a laparoscopic surgical technique for ureterocystoplasty in pediatric patients with the Mitrofanoff procedure. Patients and Methods: The procedure was performed in 4 patients (2 females and 2 males), 8-11 years old (average, 9.5 years), with a history of myelomeningocele and...

  • Botulinium toxin, as bridge to transanal pullthrough in neonate with Hirschsprungs disease. Hosseini, S. M. V.; Foroutan, H. R.; Zeraatian, S.; Sabet, B. // Journal of Indian Association of Pediatric Surgeons;Apr-Jun2008, Vol. 13 Issue 2, p69 

    Aims and Objectives: The aim of this study is to find easier way of home care while obviating the colostomy before single stage pull through operation. Materials and Methods: From August 2005 to December 2006, eight cases of neonatal Hirschsprung disease were treated. Mean age 4.5 (2-6) day/old...

  • Rationale for Using Botulinum Toxin A as an Adjunct to Upper Limb Rehabilitation in Children With Cerebral Palsy. Hoare, Brian // Journal of Child Neurology;Aug2014, Vol. 29 Issue 8, p1066 

    Cerebral palsy describes a group of disorders of movement and posture that result from disturbances in the developing brain. Although the brain lesion is nonprogressive, the secondary physical symptoms change with time and growth. If left untreated, symptoms may result in the development of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics